Post-earnings recap
Reported
Wed, Mar 12, 2025
EPS actual
$0.03
EPS est.
$-0.13
EPS surprise
+123.81%
1-day move
+0.10%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Nektar Therapeutics reported a positive EPS surprise, which contributed to a slight increase in stock price. The lack of revenue data and guidance may leave investors cautious, but the strong EPS performance suggests some underlying strength in the company's operations. The stock's modest gain reflects a mixed sentiment among investors following the earnings report.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.03 | N/A | +123.81% |
| Revenue | N/A | N/A | N/A |
Overall, management highlighted the positive EPS surprise as a sign of resilience. However, they did not provide specific revenue guidance, indicating a cautious approach.
Management expressed satisfaction with the EPS performance despite not providing revenue figures.
They emphasized ongoing efforts in research and development.